Phase III Trial Of REVLIMID In Newly Diagnosed Multiple Myeloma

Data from FIRST , an open-label phase III randomized study of continuous REVLIMID in combination with dexamethasone in patients newly diagnosed with multiple myeloma who are not candidates for stem cell transplant, have been published. The initial findings, including that the trial had met its primary endpoint of progression free survival, were reported during the plenary session at the 55th American Society of Hematology annual meeting in December 2013.

http://ift.tt/1pNAE7H